{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T04:43:44Z","timestamp":1768884224828,"version":"3.49.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s40291-024-00723-z","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T09:01:49Z","timestamp":1718701309000},"page":"501-506","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Zevorcabtagene Autoleucel: First Approval"],"prefix":"10.1007","volume":"28","author":[{"given":"Sohita","family":"Dhillon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,18]]},"reference":[{"issue":"1","key":"723_CR1","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1186\/s12885-021-08280-y","volume":"21","author":"L Zhou","year":"2021","unstructured":"Zhou L, Yu Q, Wei G, et al. Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019. BMC Cancer. 2021;21(1):606.","journal-title":"BMC Cancer"},{"issue":"2","key":"723_CR2","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.3390\/curroncol30020179","volume":"30","author":"P Bhatt","year":"2023","unstructured":"Bhatt P, Kloock C, Comenzo R. Relapsed\/refractory multiple myeloma: a review of available therapies and clinical scenarios encountered in myeloma relapse. Curr Oncol. 2023;30(2):2322\u201347.","journal-title":"Curr Oncol"},{"issue":"4","key":"723_CR3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69.","journal-title":"Blood Cancer J"},{"key":"723_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.blre.2022.100929","volume":"54","author":"S Manier","year":"2022","unstructured":"Manier S, Ingegnere T, Escure G, et al. Current state and next-generation CAR-T cells in multiple myeloma. Blood Rev. 2022;54:1\u20139.","journal-title":"Blood Rev"},{"issue":"3","key":"723_CR5","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/10428194.2023.2284088","volume":"65","author":"MJ Rees","year":"2024","unstructured":"Rees MJ, Kumar S. BCMA-directed therapy, new treatments in the myeloma toolbox, and how to use them. Leuk Lymphoma. 2024;65(3):287\u2013300.","journal-title":"Leuk Lymphoma"},{"key":"723_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.886546","volume":"13","author":"AN Khan","year":"2022","unstructured":"Khan AN, Chowdhury A, Karulkar A, et al. Immunogenicity of CAR-T cell therapeutics: evidence, mechanism and mitigation. Front Immunol. 2022;13: 886546.","journal-title":"Front Immunol"},{"key":"723_CR7","unstructured":"National Medical Products Administration. Zevorcabtagene Autoleucel Injection: NMPA Approval. 2024. https:\/\/www.nmpa.gov.cn\/datasearch\/search-info.html?nmpa=aWQ9NmZiOWU3ODJlNWI2MmIxYWFlZGJkYmFmMmM5OTA4ZGUmaXRlbUlkPWZmODA4MDgxODNjYWQ3NTAwMTg0MDg4MWY4NDgxNzlm. Accessed 24 Apr 2024."},{"key":"723_CR8","unstructured":"CARsgen. Zevorcabtagene Autoleucel Injection (\u6cfd\u6c83\u57fa\u5965\u4ed1\u8d5b\u6ce8\u5c04\u6db2): Chinese prescribing information. Shanghai: CARsgenTherapeutics Holdings Limited; 2024."},{"key":"723_CR9","unstructured":"CARsgen Therapeutics. Partnering. 2024. https:\/\/www.carsgen.com\/en\/about-us\/partnering\/. Accessed 24 Apr 2024."},{"key":"723_CR10","unstructured":"Carsgen. CARsgen Therapeutics and Huadong Medicine announce collaboration agreement for zevorcabtagene autoleucel in mainland China [media release]. 16 Jan 2023. https:\/\/www.prnewswire.com\/news-releases\/carsgen-therapeutics-and-huadong-medicine-announce-collaboration-agreement-for-zevorcabtagene-autoleucel-in-mainland-china-301722244.html."},{"issue":"8","key":"723_CR11","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.3324\/haematol.2022.280629","volume":"107","author":"M Yang","year":"2022","unstructured":"Yang M, Zhang W, Yu K, et al. A novel BCMA CAR-T-cell therapy with optimized human scFv for treatment of relapsed\/refractory multiple myeloma: results from phase I clinical trials. Haematologica. 2022;107(8):1960\u20135.","journal-title":"Haematologica"},{"key":"723_CR12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood-2020-139802","volume":"136","author":"SK Kumar","year":"2020","unstructured":"Kumar SK, Baz RC, Orlowski RZ, et al. Results from Lummicar-2: a phase 1b\/2 study of fully human B-cell maturation antigen-specific CAR T cells (CT053) in patients with relapsed and\/or refractory multiple myeloma [abstract]. Blood. 2020;136:4.","journal-title":"Blood"},{"issue":"1","key":"723_CR13","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1182\/blood-2021-150124","volume":"138","author":"WM Chen","year":"2021","unstructured":"Chen WM, Fu CC, Cai Z, et al. Sustainable efficacy and safety results from Lummicar study 1: a phase 1\/2 study of fully human B-cell maturation antigen-specific CAR T cells (CT053) in Chinese subjects with relapsed and\/or refractory multiple myeloma [abstract no. 2821 plus poster]. Blood. 2021;138(1):2821.","journal-title":"Blood"},{"key":"723_CR14","doi-asserted-by":"publisher","first-page":"4564","DOI":"10.1182\/blood-2022-168610","volume":"140","author":"WM Chen","year":"2022","unstructured":"Chen WM, Fu CC, Fang BJ, et al. Phase II study of fully human BCMA-targeting CAR-T cells (zevorcabtagene autoleucel) in patients with relapsed\/refractory multiple myeloma [abstract plus poster]. Blood. 2022;140:4564\u20135.","journal-title":"Blood"},{"key":"723_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1182\/blood-2023-184373","volume":"142","author":"CC Fu","year":"2023","unstructured":"Fu CC, Chen WM, Cai Z, et al. Three-year follow-up on efficacy and safety results from phase 1 LUMMICAR study 1 of zevorcabtagene autoleucel in Chinese patients with relapsed or refractory multiple myeloma [abstract no. 4845 plus poster]. Blood. 2023;142:3.","journal-title":"Blood"},{"key":"723_CR16","unstructured":"Chen WM, Fu CC, Fang BJ, et al. Phase 2 study of fully human BCMA-targeting CAR-T cells (zevorcabtagene autoleucel) in patients with relapsed\/refractory multiple myeloma [abstract no. S209]. In: European Hematology Association Congress. 2024."},{"key":"723_CR17","unstructured":"CARsgen Therapeutics. BCMA CAR T (zevor-cel). In: 7th Annual CAR-TCR Summit. 2022"},{"key":"723_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1182\/blood-2021-151935","volume":"138","author":"CC Fu","year":"2021","unstructured":"Fu CC, Jiang SF, Jin J, et al. Integrated analysis of B-cell maturation antigen-specific CAR T cells (CT053) in relapsed and refractory multiple myeloma subjects by high-risk factors [abstract no. 1751 plus poster]. Blood. 2021;138:3.","journal-title":"Blood"}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-024-00723-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-024-00723-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-024-00723-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T10:05:06Z","timestamp":1719482706000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-024-00723-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,18]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["723"],"URL":"https:\/\/doi.org\/10.1007\/s40291-024-00723-z","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,18]]},"assertion":[{"value":"30 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sohita Dhillon is a contracted employee of Adis International Ltd\/Springer Nature and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability"}}]}}